Journal Article
. 2011 Sep;16(10).
doi: 10.1634/theoncologist.2011-0048.

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score

Arif H Kamal 1 Charles L Loprinzi  Carol Reynolds  Amylou C Dueck  Xochiquetzal J Geiger  James N Ingle  Robert W Carlson  Timothy J Hobday  Eric P Winer  Matthew P Goetz  
Affiliations
  • PMID: 21934103
  •     18 References
  •     9 citations

Abstract

Background: Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX®; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria.

Methods: Standard demographic and tumor prognostic criteria were obtained from patients with an available RS. Two academic pathologists provided tumor grade, histologic type, and hormone receptor status. Six academic oncologists predicted the RS category (low, intermediate, or high) and provided a recommendation for therapy. The oncologists were then given the actual RS and provided recommendations for therapy. Analysis for agreement was performed.

Results: Thirty-one cases, including nine additional cases with variant pathology reads, were presented. There was substantial agreement in oncologists' ability to discriminate between true low or true intermediate and true high (κ = 0.75; p < .0001). Predictions between low and intermediate were not consistent. The most common discrepancies were predictions of a low RS risk when cases were true intermediate and predictions of an intermediate RS risk when cases were true low. The actual RS resulted in a change in the treatment recommendations in 19% of cases. Of the 186 scenarios and six oncologists in aggregate, five fewer chemotherapy recommendations resulted with the actual RS.

Conclusions: Oncologists are able to differentiate between a low or intermediate RS and a high RS using standard prognostic criteria. However, provision of the actual RS changed the treatment recommendations in nearly 20% of cases, suggesting that the RS may reduce chemotherapy use. This effect was observed in particular in intermediate-risk cases. Prospective clinical trials are necessary to determine whether decisions based on the RS change outcomes.

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer.
Jill A Foster, Maziar Abdolrasulnia, +2 authors, Linda Casebeer.
J Natl Compr Canc Netw, 2009 Jul 29; 7(7). PMID: 19635225
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Cancer statistics, 2010.
Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu, Elizabeth Ward.
CA Cancer J Clin, 2010 Jul 09; 60(5). PMID: 20610543
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening.
Miranda F Ernst, Adri C Voogd, Jan Willem W Coebergh, Jan A Roukema.
Cancer, 2004 Mar 26; 100(7). PMID: 15042665
"Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers.
Patrik Edén, Cecilia Ritz, +2 authors, Carsten Peterson.
Eur J Cancer, 2004 Aug 04; 40(12). PMID: 15288284
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
John Hornberger, Leon E Cosler, Gary H Lyman.
Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Ontario doctors' attitudes toward and use of clinical practice guidelines in oncology.
Ian D Graham, Melissa Brouwers, Christine Davies, Jacqueline Tetroe.
J Eval Clin Pract, 2007 Aug 09; 13(4). PMID: 17683303
HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Breast cancer. Clinical practice guidelines in oncology.
Robert W Carlson, D Craig Allred, +26 authors, NCCN Breast Cancer Clinical Practice Guidelines Panel.
J Natl Compr Canc Netw, 2009 Feb 10; 7(2). PMID: 19200416
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Promising new assays and technologies for the diagnosis and management of infectious diseases.
S F Mitsuma, M K Mansour, +4 authors, P Schuetz.
Clin Infect Dis, 2012 Dec 12; 56(7). PMID: 23223587    Free PMC article.
Review.
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Zsuzsanna Varga, Peter Sinn, +6 authors, Holger Moch.
PLoS One, 2013 Mar 19; 8(3). PMID: 23505515    Free PMC article.
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Salomon M Stemmer, Shmuel H Klang, +7 authors, Nicky Lieberman.
Breast Cancer Res Treat, 2013 Jun 27; 140(1). PMID: 23801158    Free PMC article.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Georgeta Fried, Mor Moskovitz.
Springerplus, 2014 Feb 26; 3. PMID: 24567880    Free PMC article.
The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.
Moo Hyun Lee, Wonshik Han, +7 authors, Eun Sook Lee.
Cancer Res Treat, 2014 Nov 11; 47(2). PMID: 25381828    Free PMC article.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
Michele M Gage, Martin Rosman, +6 authors, Lorraine Tafra.
Clin Breast Cancer, 2015 Jun 15; 15(6). PMID: 26072275    Free PMC article.
Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
Anne A Eaton, Catherine E Pesce, +5 authors, Mahmoud El-Tamer.
Breast Cancer Res Treat, 2016 Dec 09; 161(3). PMID: 27928699    Free PMC article.
Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study.
Yanna Zhang, Yidong Zhou, +2 authors, Qiang Sun.
Cancer Commun (Lond), 2020 Apr 16; 40(4). PMID: 32291973    Free PMC article.